Skip to main content
OpenTrials
Completed

NCT Number: NCT02062073

Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion

Purpose of this study will be to determine the potential of abametapir lotion to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

TKL Reserach

Paramus, New Jersey, 07652, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are healthy (to be confirmed by medical history) males or females, 18 years of age or older;
  • In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomized partner are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes;
  • If female of childbearing potential, have a negative urine pregnancy test at Day 1, and are willing to submit to a pregnancy test at the end of study;
  • Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events;
  • Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
  • Complete a patch study Medical Screening form as well as a Medical Personal History form; and
  • Read, understand, and provide signed informed consent.

Exclusion criteria

  • Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction;
  • Are not willing to refrain from using topical/systemic analgesics such as aspirin (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen will be permitted);
  • Are using inhaled/systemic/topical corticosteroids in the 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to and during the study;
  • Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications;
  • Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study;
  • Have psoriasis and/or active atopic dermatitis/eczema;
  • Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child;
  • Have a known sensitivity to constituents present in the material being evaluated;
  • Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;
  • Have received treatment for any type of internal cancer within 5 years prior to study entry;
  • Have a history of, or are currently being treated for skin cancer;
  • Are currently participating in any other clinical trial;
  • Have any known sensitivity to adhesives; and/or
  • Have received any investigational treatment(s) within 4 weeks prior to study entry.

Treatment and study plan

Abametapir Lotion 0.74% w/w

Drug

0.1% sodium lauryl sulfate

Other

saline 0.9%

Other

Vehicle Lotion

Other

Primary outcomes

  1. to evaluate the sensitizing potential of abametapir lotion using repeat insult patch test design

    Time frame: 8 weeks

    Evaluation of dermal reactions at the application sites will be assessed clinically using a visual scale that rates the degree of erythema, edema, and other signs of cutaneous irritation

Sponsors and collaborators

Lead sponsor

Dr. Reddy's Laboratories Limited

Industry

Collaborators

  • Accelovance
  • TKL Research, Inc.

Registry information

Official study title

A Randomized, Controlled Study to Evaluate the Sensitizing Potential of Abametapir Lotion in Healthy Volunteers Using a Repeat Insult Patch Test Design

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Feb 13, 2014
Registry last updated
Apr 29, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.